Across TCGA pan-cancer cohorts, REP15 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated REP15 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher REP15 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated REP15 expression acts as an unfavorable survival marker.
SKCM and CHOL are the cancer types where REP15 Mutation most reproducibly stratifies survival.